FDA Brief

Warning letters Drugs

FDA warning letter to

Kor-Chem, Inc.

High riskIssued Sep 11, 2023Posted Sep 19, 2023Division of Pharmaceutical Quality Operations II

Kor-Chem, Inc. made OTC hand sanitizer drugs with manufacturing violations, including shared equipment with industrial chemicals and missing identity and microbial testing.

What happened

FDA inspected Kor-Chem's Atlanta drug manufacturing facility from April 26 to May 5, 2023. FDA found current good manufacturing practice (CGMP) violations, including inadequate cleaning of shared equipment used for OTC hand sanitizer and corrosive industrial chemicals, missing identity tests for components such as glycerin and ethanol, missing microbial testing of each batch, and an inadequate quality unit. The firm had not sent a detailed corrective-action response, but its August 14, 2023 correspondence said it was reviewing operations and had discontinued its drug products.

What FDA found

  1. The firm failed to establish and follow adequate written cleaning and maintenance procedures for shared equipment used to make hand sanitizer and corrosive industrial chemicals.

    21 CFR 211.67(b)
  2. The firm failed to test each component lot for identity and other specifications and relied on supplier certificates of analysis without establishing their reliability; components included benzalkonium chloride, glycerin, and ethanol.

    21 CFR 211.84(d)(1) and (2)
  3. The firm failed to test each batch of hand sanitizer for objectionable microorganisms before release.

    21 CFR 211.165(b)
  4. The firm failed to establish an adequate quality unit to ensure CGMP compliance, including process validation, water system validation and monitoring, validated analytical methods, and a stability program.

    21 CFR 211.22; 211.100(a); 211.160(b); 211.166(a)

What FDA wants

FDA asks Kor-Chem to respond in writing within 15 working days describing corrections and prevention, and to provide specific risk assessments and corrective-action plans. FDA also asks for DEG and EG test results within 30 calendar days and clarification of whether the firm will resume drug manufacturing.

Who should pay attention

  • distributors and retailers selling Instant Hand Sanitizer or Handy San
  • companies that buy OTC hand sanitizer from Kor-Chem
  • quality teams at manufacturers that share equipment between drug and industrial products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk